China to Tighten Crude Steel Output Controls and Export Regulation Through 2030 
Japan Revises Economic Growth Forecast as Stimulus Fuels Consumption and Investment 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
U.S. Stock Futures Edge Higher as Holiday-Thinned Trading Persists 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown 
Japan Approves Record ¥122.3 Trillion Budget as Takaichi Seeks Fiscal Balance 
US and Japan Fast-Track $550 Billion Strategic Investment Initiative 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Researchers from the Korea Advanced Institute of Science and Technology (KAIST) have developed a wearable green organic light-emitting diode (OLED) with a 470-nanometer (nm) wavelength that can cure jaundice in infants.
The OLED provides sufficient power for jaundice treatment even at low voltage, durability for over 100 hours of operation, a low operating temperature of less than 35 Celsius degrees, and flexibility that can endure over 1,000 bends at a 2 mm radius of curvature.
The bilirubin level of the infants’ serum reaches 12 milligrams per decilitre (mg/dL) within three hours of being exposed to the OLED, indicating the completed treatment of jaundice.
Unlike existing light-emitting diode (LED)-based jaundice treatment devices currently used at hospitals, the OLED showed uniform and effective treatment functions.
